Eli Lilly said it expects full-year 2024 worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year and is $4.0 billion above the midpoint of first-time 2024 financial guidance.

1. 01

   Eli Lilly said it expects full-year 2024 worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year and is $4.0 billion above the midpoint of first-time 2024 financial guidance.

2. 02

   The company said Q4 2024 revenue is expected to be approximately $13.5 billion, representing growth of 45% compared to the same quarter last year, and includes approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound. It added that this is approximately $400 million below the low end of recently issued financial guidance.

3. 03

   The company explained that its previous guidance had anticipated faster acceleration of growth than the U.S. incretin market growth of 45% compared to the same quarter last year, and that lower-than-expected channel inventory at year-end contributed to its Q4 results.

4. 04

   Eli Lilly said it anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, which represents growth of 32% at the midpoint compared to expected 2024 revenue. The company said it currently plans to share its full Q4 financial results and 2025 financial guidance on February 6, 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.